lenograstim + docetaxel

Lenograstim + docetaxel is a **combination regimen** used primarily in the treatment of solid tumors such as breast cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, and head or neck cancer. Lenograstim is a recombinant human granulocyte-colony stimulating factor (G-CSF) that stimulates neutrophil production, thereby reducing the incidence and severity of chemotherapy-induced neutropenia. Docetaxel is a semi-synthetic taxoid antineoplastic agent that acts by promoting and stabilizing microtubule assembly, thereby inhibiting mitosis and inducing cell death in rapidly dividing tumor cells. Lenograstim is used as a primary prophylaxis for neutropenia and febrile neutropenia when administering docetaxel-based chemotherapy, allowing higher dosing intensity and reducing the interval between cycles[1][3][5]. This enables patients to maintain optimal chemotherapy schedules with manageable toxicities and improved exposure, thereby benefitting overall survival[1][3][5].

Brand names

Docetere

Other names

lenograstimdocetaxel